Personalized medicine for advanced prostate cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10576
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: The University of Tokyo
• Principal Investigator: Fujimura Tetsuya 東京大学, 医学部附属病院, 准教授 (50376448)
• Co-Investigator(Kenkyū-buntansha): 浦野 友彦 国際医療福祉大学, 医学部, 主任教授 (20334386) ; 高山 賢一 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (50508075)
• Co-Investigator(Renkei-kenkyūsha): Inoue Satoshi 東京大学, 医学部附属病院, 特任教授 (40251251) ; Yamada Yuta 東京大学, 医学部附属病院, 助教 (10376452) ; Kumagai Jimpei 東京大学, 医学部附属病院, 助教 (10323552) ; Takahashi Satoru 日本大学, 医学部附属病院, 教授 (50197141)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 前立腺癌 / アンドロゲン / エストロゲン / ドセタキセル

Outline of Final Research Achievements

Although long non-coding RNAs (lncRNAs) have been associated with a variety of cancers, the interplay between lncRNAs and androgen receptor signaling in prostate cancer is still unclear. We identified an androgen-dependent lncRNA, POTEF-AS1, whose expression was regulated by androgen receptor in two androgen-dependent cells by using directional RNA sequencing analysis. POTEF-AS1 promoted cell growth, repressed genes related to the Toll-like receptor signaling and apoptosis pathways, and inhibited apoptosis in docetaxel-treated LNCaP cells. These findings suggest that POTEF-AS1 would play a key role in the progression of prostate cancer by repressing Toll-like receptor signaling.

Free Research Field

前立腺癌